Ganga Pharmaceuticals Limited

GANGAPHARM6

INE615T01017

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:55 24/06/2024 pm IST			5-day change	1st Jan Change
24.67 ^INR	-.--%		-.--%	-13.41%

16/05	Ganga Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI
19/01	Ganga Pharmaceuticals Limited announced that it has received INR 17.0625 million in funding from Lenus Finvest Pvt Ltd, Plutus Capital Management Llp	CI

Ganga Pharmaceuticals Limited Appoints Priti Kothari Bhaiya as Company Secretary and Compliance Officer to Replace Mustafa Shabbir Badami

March 22, 2016 at 06:17 pm IST

Ganga Pharmaceuticals Ltd. announced that Ms. Priti Kothari Bhaiya, has been appointed as Company Secretary and Compliance Officer of the company as required in terms of the provisions of the Companies Act 2013 and of SEBI listing regulation in place Mr. Mustafa Shabbir Badami who had resigned from the post of the Company Secretary and Compliance Officer of the company.

Latest news about Ganga Pharmaceuticals Limited

Ganga Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024	16/05	CI
Ganga Pharmaceuticals Limited announced that it has received INR 17.0625 million in funding from Lenus Finvest Pvt Ltd, Plutus Capital Management Llp	19/01	CI
Ganga Pharmaceuticals Limited announced that it expects to receive INR 21 million in funding from Lenus Finvest Pvt Ltd, Plutus Capital Management Llp	04/12	CI
Ganga Pharmaceuticals Board to Consider Issuing Equity, Convertible Warrants to Raise Funds	27/11	MT
Ganga Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended September 30, 2023	08/11	CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2023	22/23/22	CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended September 30, 2022	11/22/11	CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2022	25/22/25	CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2021	28/21/28	CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended September 30, 2020	05/20/05	CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2020	27/20/27	CI
Ganga Pharmaceuticals Limited Announces Management Changes	25/20/25	CI
Ganga Pharmaceuticals Limited Announces the Appointment and Re-Designation of Sanjay Kulkarni as Executive Director	27/19/27	CI
Ganga Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2019	13/19/13	CI
874,550 equity shares of Ganga Pharmaceuticals Limited are subject to a Lock-Up Agreement Ending on 23-FEB-2019.	23/19/23	CI
Ganga Pharmaceuticals Limited Reports Unaudited Standalone Earnings Results for the Half Year Ended September 30, 2018	05/18/05	CI
Ganga Pharmaceuticals Limited Appoints Anagh B. Sharma as Chief Financial Officer	06/18/06	CI
Ganga Pharmaceuticals Limited Announces Resignation of Ganesh Jyothimani Paradeshi, Chief Financial Officer	30/18/30	CI
Ganga Pharmaceuticals Limited Announces Audited Standalone Earnings Results for the Half Year and Full Year Ended March 31, 2018	28/18/28	CI
Ganga Pharmaceuticals Limited Reports Unaudited Standalone Earnings Results for the Half Year Ended September 30, 2017	09/17/09	CI
Ganga Pharmaceuticals Limited Reports Audited Earnings Results for Fourth Quarter and Full Year Ended March 31, 2017	22/17/22	CI
2,106,950 equity of Ganga Pharmaceuticals Limited are subject to a Lock-Up Agreement Ending on 23-FEB-2017.	23/17/23	CI
Ganga Pharmaceuticals Limited Reports Unaudited Standalone Earnings Results for the Half Year Ended September 30, 2016	08/16/08	CI
Ganga Pharmaceuticals Limited Reports Audited Standalone Earnings Results for the Half Year and Full Year Ended March 31, 2016	27/16/27	CI
Ganga Pharmaceuticals Limited Appoints Priti Kothari Bhaiya as Company Secretary and Compliance Officer to Replace Mustafa Shabbir Badami	22/16/22	CI

Chart Ganga Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

Ganga Pharmaceuticals Limited is an India-based company, which is engaged in the production of ayurvedic medicines. The Company is also into marketing and distribution of ayurvedic medicines. It offers ayurvedic medicines in various categories, including acidity, antidandruff, antioxidants, blood purifier and skin disorder, constipation, cough and cold, dental care, diarrhea, ear care, female tonic, hair care, hemorrhoids and piles, indigestion, iron tonic, joint pains, kidney stone, liver disorder, rejuvenation tonic, sleep inducers, and herbal cosmetics. Its products include Asuka tablets, Dendroil, Ashwo tablets - tonic for body and mind, Raktaj tablets/syrup - for skin disorders, Nirmalaya (proprietary) - relieves constipation, Khadira tablets (80 mg.) (A.S.S) - relieves cough, Danta Doshahar Manjan - gum and teeth protective, Holetrica capsule - checks diarrhea and corrects digestion, Karnaraj drops (proprietary) - ear drops, Femoherb syrup/tablets, and Mahabhrungraj oil.

Sector

Pharmaceuticals

Calendar

07/11/2024 - Q2 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GANGA PHARMACEUTICALS LIMITED	-13.41%	14.29L
ELI LILLY AND COMPANY	+56.89%	82TCr
NOVO NORDISK A/S	+39.52%	63TCr
JOHNSON & JOHNSON	-6.55%	35TCr
MERCK & CO., INC.	+15.99%	32TCr
ABBVIE INC.	+7.92%	30TCr
ASTRAZENECA PLC	+13.74%	24TCr
NOVARTIS AG	+13.83%	22TCr
ROCHE HOLDING AG	-0.49%	22TCr
AMGEN INC.	+7.94%	17TCr